Huang, H., Xu, Y., Guo, Z., Zhang, M., Li, W., Song, Y., Nie, J., Hu, W., Hei, T. K., & Zhou, G. (2025). Irradiation-responsive PRDM10-DT modulates the angiogenic response in human NSCLC cells in an SP1-dependent manner via the miR-663a/TGF-β1 axis. Journal of Translational Medicine, 23(1). https://doi.org/10.1186/s12967-025-06273-0

Mondal, J., Zhang, J., Qing, F., Li, S., Kumar, D., Huse, J. T., & Giancotti, F. G. (2025). Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56347-2

Zhuang, X., Wang, Q., Joost, S., Ferrena, A., Humphreys, D. T., Li, Z., Blum, M., Krause, K., Ding, S., Landais, Y., Zhan, Y., Zhao, Y., Chaligne, R., Lee, J.-H., Carrasco, S. E., Bhanot, U. K., Koche, R. P., Bott, M. J., Katajisto, P., … Tammela, T. (2024). Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis. Nature, 637(8044), 184–194. https://doi.org/10.1038/s41586-024-08285-0

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Jain, S., Bai, X., Mallick, S., Kinghorn, B., May, B., Yao, A. G., Allen-Gipson, D., Zhang, X., Henick, B. S., Momen-Heravi, F., Carrot-Zhang, J., & Taylor, A. M. (2024). Amplification of MYC and Its Enhancer Correlates With Genetic Ancestry in Lung Squamous Cell Carcinoma. JCO Precision Oncology, 8. https://doi.org/10.1200/po.24.00223

Faiena, I., Adhikary, S., Schweitzer, C., Astrow, S. H., Grogan, T., Funt, S. A., Bot, A., Dorff, T., Rosenberg, J. E., Elashoff, D. A., Pantuck, A. J., & Drakaki, A. (2024). Gene and Protein Expression of MAGE and Associated Immune Landscape Elements in Non–Small-Cell Lung Carcinoma and Urothelial Carcinomas. Journal of Immunotherapy. https://doi.org/10.1097/cji.0000000000000538

Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices. (2024). Clinical Journal of Oncology Nursing. https://doi.org/10.1188/24.cjon.1-8.ap

Heymann, J. J., D’Ambrosio, D., Dombrowski, K. S., Desai, N., & Illei, P. B. (2024). Pulmonary Cytopathology. Surgical Pathology Clinics, 17(3), 395–410. https://doi.org/10.1016/j.path.2024.06.002

Desai, N., D’Ambrosio, D., Dombrowski, K. S., Illei, P. B., & Heymann, J. J. (2024). Pulmonary Cytopathology. Surgical Pathology Clinics, 17(3), 411–429. https://doi.org/10.1016/j.path.2024.06.003

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284

Santibanez, V., Salvatore, M., & Padilla, M. (2024). Late to the Game: Cancer Screening Guidelines and Nodule Surveillance in Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 210(4), 390–391. https://doi.org/10.1164/rccm.202403-0531vp

Kinslow, C. J., ll, M. B., Cai, Y., Yan, J., Lorkiewicz, P. K., Al-Attar, A., Tan, J., Higashi, R. M., Lane, A. N., & Fan, T. W.-M. (2024). Stable isotope-resolved metabolomics analyses of metabolic phenotypes reveal variable glutamine metabolism in different patient-derived models of non-small cell lung cancer from a single patient. Metabolomics, 20(4). https://doi.org/10.1007/s11306-024-02126-x

Quintanal-Villalonga, A., Kawasaki, K., Redin, E., Uddin, F., Rakhade, S., Durani, V., Sabet, A., Shafer, M., Karthaus, W. R., Zaidi, S., Zhan, Y. A., Manoj, P., Sridhar, H., Kinyua, D., Zhong, H., Mello, B. P., Ciampricotti, M., Bhanot, U. K., Linkov, I., … Rudin, C. M. (2024). CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01908-y

Saqi, A., Liu, Y., Politis, M. G., Salvatore, M., & Jambawalikar, S. (2024). Combined expert-in-the-loop—random forest multiclass segmentation U-net based artificial intelligence model: evaluation of non-small cell lung cancer in fibrotic and non-fibrotic microenvironments. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05394-2

Heath, H., Yoo, J. Y., Akter, S., Jain, A., Sharma, V., McGee, H., Soliman, A., Mahmoud, A. M., Matthews, A. K., Winn, R. A., Madak-Erdogan, Z., & Kim, S. J. (2024). The Effect of Exposure to Neighborhood Violence on Glucocorticoid Receptor Signaling in Lung Tumors. Cancer Research Communications, 4(7), 1643–1654. https://doi.org/10.1158/2767-9764.crc-24-0032

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Li, C.-C., Manella, J., Kefi, S. E., & Matthews, A. K. (2024). Does the revised LDCT lung cancer screening guideline bridge the racial disparities gap: Results from the health and retirement study. Journal of the National Medical Association, 116(2), 180–188. https://doi.org/10.1016/j.jnma.2024.01.008

Kim, C., Wang, X.-D., Liu, Z., Hao, J., Wang, S., Li, P., Zi, Z., Ding, Q., Jang, S., Kim, J., Luo, Y., Huffman, K. E., Pal Choudhuri, S., del Rio, S., Cai, L., Liang, H., Drapkin, B. J., Minna, J. D., & Yu, Y. (2024). Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science Advances, 10(3). https://doi.org/10.1126/sciadv.adh2579

Salvatore, M. M., Liu, Y., Peng, B., Hsu, H. Y., Saqi, A., Tsai, W.-Y., Leu, C.-S., & Jambawalikar, S. (2024). Comparison of lung cancer occurring in fibrotic versus non-fibrotic lung on chest CT. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-023-04645-y

Liu, Y., Hsu, H. Y., Lin, T., Peng, B., Saqi, A., Salvatore, M. M., & Jambawalikar, S. (2024). Lung nodule malignancy classification with associated pulmonary fibrosis using 3D attention-gated convolutional network with CT scans. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-023-04798-w

Liu, M. A., Xu, E., & Shu, C. A. (2023). A case study on severe psychiatric symptoms induced by lorlatinib. Psycho-Oncology, 33(1). Portico. https://doi.org/10.1002/pon.6283

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., Christos, P. J., Saxena, A., Elemento, O., Bhinder, B., Ager, C., Amin, A. D., Sanfilippo, N. J., Mittal, V., Borczuk, A. C., … McGraw, T. E. (2023). Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44195-x

Efe, G., Dunbar, K. J., Sugiura, K., Cunningham, K., Carcamo, S., Karaiskos, S., Tang, Q., Cruz-Acuña, R., Resnick-Silverman, L., Peura, J., Lu, C., Hasson, D., Klein-Szanto, A. J., Taylor, A. M., Manfredi, J. J., Prives, C., & Rustgi, A. K. (2023). p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression. Cancer Discovery, 13(12), 2632–2651. https://doi.org/10.1158/2159-8290.cd-23-0601

Kinslow, C. J., Wang, Y., Liu, Y., Zuev, K. M., Chaudhary, K. R., Wang, T. J. C., Donalek, C., Amori, M., & Cheng, S. K. (2023). Influenza activity and regional mortality for non-small cell lung cancer. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-47173-x

González-Ruíz, J., A.Baccarelli, A., Cantu-de-Leon, D., & Prada, D. (2023). Air Pollution and Lung Cancer: Contributions of Extracellular Vesicles as Pathogenic Mechanisms and Clinical Utility. Current Environmental Health Reports, 10(4), 478–489. https://doi.org/10.1007/s40572-023-00421-8

Oxnard, G. R., Chen, R., Pharr, J. C., Koeller, D. R., Bertram, A. A., Dahlberg, S. E., Rainville, I., Shane-Carson, K., Taylor, K. A., Sable-Hunt, A., Sholl, L. M., Teerlink, C. C., Thomas, A., Cannon-Albright, L. A., Fay, A. P., Ashton-Prolla, P., Yang, H., Salvatore, M. M., Addario, B. J., … Garber, J. E. (2023). Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology, 41(34), 5274–5284. https://doi.org/10.1200/jco.23.01372

Kostyrko, K., Román, M., Lee, A. G., Simpson, D. R., Dinh, P. T., Leung, S. G., Marini, K. D., Kelly, M. R., Broyde, J., Califano, A., Jackson, P. K., & Sweet-Cordero, E. A. (2023). UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39591-2

Kim, S. J., Kery, C., An, J., Rineer, J., Bobashev, G., & Matthews, A. K. (2024). Racial/Ethnic disparities in exposure to neighborhood violence and lung cancer risk in Chicago. Social Science & Medicine, 340, 116448. https://doi.org/10.1016/j.socscimed.2023.116448

Wolf, A. M. D., Oeffinger, K. C., Shih, T. Y., Walter, L. C., Church, T. R., Fontham, E. T. H., Elkin, E. B., Etzioni, R. D., Guerra, C. E., Perkins, R. B., Kondo, K. K., Kratzer, T. B., Manassaram‐Baptiste, D., Dahut, W. L., & Smith, R. A. (2023). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 74(1), 50–81. Portico. https://doi.org/10.3322/caac.21811

Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Lopez, J. M., Roden, A. C., Sholl, L., Weissferdt, A., Posadas, J., Walker, A., Zhu, H., Wijeratne, M. T., Connolly, C., Wynes, M., Bota-Rabassedas, N., … Wistuba, I. (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017

Domingo-Relloso, A., Joehanes, R., Rodriguez-Hernandez, Z., Lahousse, L., Haack, K., Fallin, M. D., Herreros-Martinez, M., Umans, J. G., Best, L. G., Huan, T., Liu, C., Ma, J., Yao, C., Jerolon, A., Bermudez, J. D., Cole, S. A., Rhoades, D. A., Levy, D., Navas-Acien, A., & Tellez-Plaza, M. (2023). Smoking, blood DNA methylation sites and lung cancer risk. Environmental Pollution, 334, 122153. https://doi.org/10.1016/j.envpol.2023.122153

Liu, Y., Mullangi, S., Debono, D., Chen, X., Pham, T., Fisch, M. J., Gordon, A. S., & Hershman, D. L. (2023). Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors. JCO Oncology Practice, 19(9), 731–740. https://doi.org/10.1200/op.23.00199

Rusthoven, C. G., Staley, A. W., Gao, D., Yomo, S., Bernhardt, D., Wandrey, N., El Shafie, R., Kraemer, A., Padilla, O., Chiang, V., Faramand, A. M., Palmer, J. D., Zacharia, B. E., Wegner, R. E., Hattangadi-Gluth, J. A., Levy, A., Bernstein, K., Mathieu, D., Cagney, D. N., … Yamamoto, M. (2023). Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). JNCI: Journal of the National Cancer Institute, 115(8), 926–936. https://doi.org/10.1093/jnci/djad073

Lieberman-Cribbin, W., & Taioli, E. (2023). Epidemiologic roadblocks in studying elongated mineral particles and mesothelioma risk. Environmental Research, 230, 115086. https://doi.org/10.1016/j.envres.2022.115086

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, M. J., Chakrabarti, T., Scott, S. C., Bironzo, P., Scheffler, M., Christopoulos, P., Stenzinger, A., … Skoulidis, F. (2023). Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discovery, 13(7), 1556–1571. https://doi.org/10.1158/2159-8290.cd-22-1420

DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023). Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. Cancer Research, 83(12), 1953–1967. https://doi.org/10.1158/0008-5472.can-22-3848

Thummalapalli, R., Bernstein, E., Herzberg, B., Li, B. T., Iqbal, A., Preeshagul, I., Santini, F. C., Eng, J., Ladanyi, M., Yang, S.-R., Shen, R., Lito, P., Riely, G. J., Sabari, J. K., & Arbour, K. C. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 7. https://doi.org/10.1200/po.23.00030

Fong, A. J., Llanos, A. A. M., Ashrafi, A., Zeinomar, N., Chokshi, S., Bandera, E. V., Devine, K. A., Hudson, S. V., Qin, B., O’Malley, D., Paddock, L. E., Stroup, A. M., Evens, A. M., & Manne, S. L. (2023). Sociodemographic and Health Correlates of Multiple Health Behavior Adherence among Cancer Survivors: A Latent Class Analysis. Nutrients, 15(10), 2354. https://doi.org/10.3390/nu15102354

May, M. S., Jamison, J. K., Wong, W., Michel, A., Raufi, A. G., Neugut, A. I., & Manji, G. A. (2023). Smoking is Not Associated with Lung Metastasis in Pancreatic Cancer. Cancer Investigation, 41(5), 487–490. https://doi.org/10.1080/07357907.2023.2203747

Zhao, W., Ma, J., Zhao, L., Hou, R., Qiu, L., Fu, X., & Zhao, J. (2023). PUNDIT: Pulmonary nodule detection with image category transformation. Medical Physics, 50(5), 2914–2927. Portico. https://doi.org/10.1002/mp.16183

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., … Gainor, J. F. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 55(5), 807–819. https://doi.org/10.1038/s41588-023-01355-5

Dercle, L., Fronheiser, M., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., Zhao, B., & Leung, D. K. (2023). Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. Journal of Thoracic Oncology, 18(5), 587–598. https://doi.org/10.1016/j.jtho.2022.12.019

Pei, H., Dai, Y., Yu, Y., Tang, J., Cao, Z., Zhang, Y., Li, B., Nie, J., Hei, T. K., & Zhou, G. (2023). The Tumorigenic Effect of lncRNA AFAP1‐AS1 is Mediated by Translated Peptide ATMLP Under the Control of m6A Methylation. Advanced Science, 10(13). Portico. https://doi.org/10.1002/advs.202300314

Herzberg, B. O., & Manji, G. A. (2023). KRAS: Druggable at Last. The Oncologist, 28(4), 283–286. https://doi.org/10.1093/oncolo/oyad014

Lee, S. M., Fan, W., Wang, A., Vaidya, R., Redman, M. W., Gettinger, S. N., Bazhenova, L., Herbst, R. S., Hershman, D. L., & Unger, J. M. (2023). Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clinical Cancer Informatics, 7. https://doi.org/10.1200/cci.22.00165

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

Li, C.-C., Matthews, A. K., Gao, X., & Cheung, K. (2023). Preliminary Testing of A Web-Based Lung Cancer Screening Decision Coaching Tool for Older Chinese American Smokers and Their Providers. Journal of the National Medical Association, 115(2), 223–232. https://doi.org/10.1016/j.jnma.2023.01.009

Hosseini, M., & Salvatore, M. (2023). Is pulmonary fibrosis a precancerous disease? European Journal of Radiology, 160, 110723. https://doi.org/10.1016/j.ejrad.2023.110723